A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety of YM543 in type 2 Diabetes Mellitus patients and to investigate whether this study drug is effective in these patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Treatment-naive subjects diagnosed with T2DM

• Stable diet and exercise program for at least 6 weeks

• Inadequate glycemic control indicated by HbA1c and FPG level at Visit 1

Exclusion Criteria:

• Any known complication of T2DM indicating a late disease state, clinical manifestations of macro- and/or micro vascular disorders

• Use of insulin or oral blood glucose lowering drugs in the last 3 months